Access To Medicine Foundation

Often searched

Index ranking

Vacancies

10 year analysis

  • Healthcare inequity
    • How big is the problem?
    • How we drive change
    • Our story
    • Our impact
    • How big is the problem?
    • How we drive change
    • Our story
    • Our impact
  • Become a catalyst
    • Investors
    • Companies
    • Government & policymakers
    • Events & engagements
    • Investors
    • Companies
    • Government & policymakers
    • Events & engagements
  • Sectors and research
    • R&D-based pharma companies
    • Medical gas companies
    • Generic medicine manufacturers
    • Diagnostics companies
    • Vaccine manufacturers
    • Resource centre
    • Company profiles & report cards
    • R&D-based pharma companies
    • Medical gas companies
    • Generic medicine manufacturers
    • Diagnostics companies
    • Vaccine manufacturers
    • Resource centre
    • Company profiles & report cards
  • Cross-Sector Programmes
    • Antimicrobial resistance
    • Diabetes care
    • Antimicrobial resistance
    • Diabetes care
  • On the pulse of global health
    • Access insights
    • The Health Equity podcast
    • Access insights
    • The Health Equity podcast
  • News
  • Our team
  • Featured insights
  • Governance & financials
  • Vacancies
  • Media coverage
  • FAQ
  • Contact us

Poor countries desperately need better access to generic medicines

As the Access to Medicine Foundation publishes the first ever analytical framework specifically for generic and biosimilar medicine manufacturers, Jayasree Iyer, CEO, writes for the Financial Times about why this is important.

Date

15 February 2023

Direct links

Read the article

Generic and biosimilar medicine manufacturers can play a critical role in ensuring people around the world have access to a reliable and affordable supply of quality-assured medicines. In February 2023, the Access to Medicine Foundation launched a new analytical framework to assess, track and guide manufacturers’ efforts to expand access to their products in low- and middle-income countries (LMICs), putting these companies’ central position in the global health landscape under the spotlight.

The article describes the opportunities that are available to generics companies and the need for them to make a conscious effort to address global health challenges and realise their potential as key players in access to medicine.

"We know this is possible, because generics companies are already experts at delivering lower-cost treatments at scale, and have stepped up previously to address urgent issues."

Read the article on the Financial Times website.

Divya Verma

Head of Communications

dverma@accesstomedicinefoundation.org

Get in touch

Sectors & research

Learn more about our Generic & Biosimilar Medicines Programme
Featured News

First-of-its-kind framework to assess how generics manufacturers expand access to medicine

15 February 2023
Event

Joint event with World Economic Forum on the evolving role of generics – Meeting Report

21 June 2023

Access to Medicine Foundation

Interested in our work?

Access to Medicine Foundation is funded by

Terms & conditions

Privacy & cookie policy

Disclaimer

Copyright 2004 - 2025 Access to Medicine Foundation - All Rights Reserved